This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.
Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within the expanding DNA Damage Response (“DDR”) oncology market through development of ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to an BioMedWire editorial, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030. The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development across multiple cancer indications.
The editorial noted that ONC010(TM) has demonstrated encouraging preclinical results, including extended survival and tumor growth reduction in colorectal cancer models, while the company advances manufacturing, formulation and IND-enabling activities through partnerships with Dalton Pharma Services and Nucro-Technics. Onco-Innovations also acquired Inka Health Corp., whose SynoGraph(TM) causal AI platform is designed to support patient stratification and clinical trial design as the company prepares for anticipated first-in-human studies. The report highlighted continued innovation across the biotechnology sector, citing recent regulatory and clinical milestones reported by Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), GSK plc (NYSE: GSK) and Gilead Sciences Inc. (NASDAQ: GILD).
To view the full press release, visit https://ibn.fm/8tbSk
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN